Page last updated: 2024-12-06

cefotetan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cefotetan is a second-generation cephalosporin antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. It is administered intravenously or intramuscularly. Cefotetan is synthesized through a multi-step process involving chemical reactions to modify the cephalosporin nucleus. Its primary mechanism of action involves inhibiting the synthesis of peptidoglycans, essential components of bacterial cell walls. Cefotetan is effective against a wide range of bacterial infections, including skin and soft tissue infections, urinary tract infections, pelvic inflammatory disease, and intra-abdominal infections. It is particularly useful in treating infections caused by anaerobic bacteria. Cefotetan is studied extensively due to its unique pharmacokinetic properties, including a long half-life and good tissue penetration. Its potential benefits in treating various infections make it a valuable therapeutic option in clinical practice. However, it is important to note that cefotetan can cause adverse effects, such as gastrointestinal disturbances, hypersensitivity reactions, and bleeding complications. It is contraindicated in individuals with known allergies to cephalosporins.'

Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID53025
CHEMBL ID474579
CHEBI ID3499
SCHEMBL ID61376
MeSH IDM0023580

Synonyms (92)

Synonym
AC-2141
cefotetanum
7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
chebi:3499 ,
smr001233197
MLS002153829 ,
ici-156834
BSPBIO_000606
(6r,7s)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cas-69712-56-7
NCGC00016914-01
PRESTWICK2_000473
BPBIO1_000668
NCGC00179507-01
PRESTWICK3_000473
AB00513847
69712-56-7
cefotetan
C06886
(6r,7s)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid
DB01330
D00260
cefotetan (jp17/usp/inn)
einecs 274-093-3
(6r,7s)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
ici 156834
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl)carbonyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7alpha))-
brn 1208088
(6r,7s)-4-((2-carboxy-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-7-yl)carbamoyl)-1,3-dithietane-delta(sup 2,alpha)-malonamic acid
cefotetanum [inn-latin]
c17h17n7o8s4
ici 156,834
SPBIO_002545
PRESTWICK0_000473
PRESTWICK1_000473
CHEMBL474579
nsc-760045
ici-156,834
HMS1569O08
disodium 7-[[4-(2-amino-1-carboxylato-2-oxo-ethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
A836615
HMS2096O08
ici156834
apacef
nsc 760045
cefotetan [usan:usp:inn:ban]
48spp0pa9q ,
unii-48spp0pa9q
tox21_110681
dtxcid202762
dtxsid1022762 ,
HMS2234C15
AKOS015896100
(6r,7s)-7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CCG-220473
SCHEMBL61376
cefotetan, antibiotic for culture media use only
W-104601
(6r,7s)-7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]-oxomethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cid_53025
(6r,7s)-7-[[4-[1-azanyl-3-oxidanyl-1,3-bis(oxidanylidene)propan-2-ylidene]-1,3-dithietan-2-yl]carbonylamino]-7-methoxy-3-[(1-methyl-1,2,3,4-tetrazol-5-yl)sulfanylmethyl]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7s)-7-[[4-(2-amino-1-carboxy-2-keto-ethylidene)-1,3-dithietane-2-carbonyl]amino]-8-keto-7-methoxy-3-[[(1-methyltetrazol-5-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7s)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
bdbm80643
C2936
(6r,7s)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
sr-01000842155
SR-01000842155-3
mfcd00864983
HMS3713O08
(6r,7s)-7-(4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carboxamido)-7-methoxy-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefotetan acid
Q2602246
BCP10745
AMY28799
gtpl10936
NCGC00016914-06
CS-0092723
HY-N6670
AS-56133
EN300-19766312
(6r,7s)-7-{4-[carbamoyl(carboxy)methylidene]-1,3-dithietane-2-amido}-7-methoxy-3-{[(1-methyl-1h-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefotetan [mart.]
cefotetan [usan]
cefotetan [jan]
(6r,7s)-4-((2-carboxy-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-7-yl)carbamoyl)-1,3-dithietane-.delta.(sup 2,.alpha.)-malonamic acid
cefotetan [inn]
cefotetan [usp impurity]
cefotetan [usp monograph]
cefotetan [vandf]
cefotetan [mi]
cefotetan [who-dd]

Research Excerpts

Overview

Cefotetan is a semisynthetic cephalosporin with a broad spectrum of Gram-negative and anaerobic activity. It is a safe and effective antibiotic for use as prophylaxis in elective colorectal surgery.

ExcerptReferenceRelevance
"Cefotetan appears to be a promising, beta-lactam compound with some in vitro characteristics comparable to the 1-oxa-beta-lactams and alpha-methoxyimino cephalosporins."( Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobials.
Jones, RN; Wilson, HW, 1983
)
1.21
"Cefotetan is a new cephamycin whose interaction with a group of eight beta-lactamases isolated from various Gram-negative bacteria has been studied. "( Cefotetan and beta-lactamases. I. An analysis of the affinity of cefotetan for beta-lactamases.
Doré, JC; Labia, R; Morand, A; Verchere-Beaur, C, 1983
)
3.15
"Cefotetan (CTT) is a new parenteral semisynthetic cephamycin-type antibiotic with a broad antibacterial spectrum against both Gram-positive and Gram-negative bacteria. "( [Cefotetan, a new cephamycin antibiotic: in vitro and in vivo antibacterial activities (author's transl)].
Naito, S; Ohmi, Y; Saito, M; Suzaki, K; Toda, M; Yano, K, 1982
)
2.62
"Cefotetan is a new, potent, 7 alpha-methoxy cephalosporin (cephamycin). "( Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
Ayers, LW; Barry, AL; Fuchs, PC; Gavan, TL; Gerlach, EH; Jones, RN; Sommers, HM; Thornsberry, C, 1982
)
3.15
"Cefotetan is a 7-alpha-methoxy beta-lactam. "( Clinical pharmacokinetics of cefotetan.
Albanese, J; Martin, C; Thomachot, L, 1994
)
2.02
"Cefotetan is a safe and effective antibiotic for use as prophylaxis in elective colorectal surgery."( A randomized prospective study to compare cefotetan with cefuroxime plus metronidazole as prophylaxis in elective colorectal surgery.
Karran, SJ; Skipper, D, 1992
)
1.27
"Cefotetan is a semisynthetic cephalosporin with a broad spectrum of Gram-negative and anaerobic activity. "( Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers.
Carver, PL; Nightingale, CH; Quintiliani, R, 1989
)
1.95
"Cefotetan is a cephamycin antibiotic theoretically suited to prophylaxis of wound infection during upper elective gastrointestinal surgery. "( A comparative trial between cefotetan and cephazolin for wound sepsis prophylaxis during elective upper gastrointestinal surgery with an investigation of cefotetan penetration into the obstructed biliary tree.
Cooper, MJ; Leaper, DJ; Turner, A, 1986
)
2.01
"Cefotetan is a new cephamycin antibiotic characterised by excellent B-lactamase stability and anti-anaerobe activity, coupled with a long half life of 3-4 h which permits twice daily dosage. "( Organisms isolated from severe odontogenic soft tissue infections: their sensitivities to cefotetan and seven other antibiotics, and implications for therapy and prophylaxis.
Hearn, B; Quayle, AA; Russell, C, 1987
)
1.94
"Cefotetan is a newly developed cephamycin especially resistant to bacterial beta-lactamase. "( Evaluation of cefotetan in uncomplicated gonorrhea.
Abeck, D; Korting, HC; Neubert, U, 1986
)
2.07
"Cefotetan is a promising and effective antimicrobial agent in the therapy of biliary tract infections."( Clinical and pharmacokinetic study of cefotetan in biliary tract infections: preliminary report.
Altucci, P; Cristiano, P; De Ascentis, G; Iovene, MR; Lobello, R; Manguso, L; Paradisi, F, 1988
)
1.27
"Cefotetan is a semi-synthetic cephamycin antibiotic. "( Treatment of bacterial peritonitis.
Guastella, T; Licata, A; Nicoletti, G; Puleo, S; Rodolico, G; Scilletta, B, 1988
)
1.72
"Cefotetan is a broad spectrum cephamycin antibiotic with a long serum half-life (3-4.5 h): this is explained, in part, by serum-protein-binding (SPB) of 88%. "( Cefotetan: antibacterial activity against Staphylococcus aureus in the presence of human serum.
Edwards, JR, 1988
)
3.16
"Cefotetan is a recently introduced cephamycin antibiotic for parenteral administration, with a broad spectrum of antibacterial activity. "( Cefotetan: comparative and noncomparative studies in obstetric and gynecologic infections.
Knuppel, RA; Lake, M; O'Bryan, D, 1988
)
3.16
"Cefotetan (CTT) is a cephem antibiotic with the above mentioned side chain at the 3 position."( [Effects of cefotetan on PIVKA-II changes in the treatment of infections and prophylaxis of surgical infections in the fields of obstetrics and gynecology].
Chimura, T; Hirayama, T; Morisaki, N, 1987
)
1.37
"Cefotetan is a cephamycin and was found resistant to all 14 plasmid-mediated and 2 chromosomally-mediated beta-lactamases."( The beta-lactamase stability and in vitro activity of cefotetan; a comparison with 8 other beta-lactam antibiotics and gentamicin.
Benzon, MW; Friis, H; Prag, J; Togsverd, E, 1986
)
1.24
"Cefotetan is a new semisynthetic cephamycin antibiotic administered intravenously or intramuscularly. "( Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Richards, DM; Ward, A, 1985
)
3.15

Effects

Cefotetan disodium has been given by zero order intravenous infusion at 75.8 mg/h to four healthy male volunteers over a 24-h period. The drug has shown good clinical efficacy in intra-abdominal, obstetric and gynaecological infections, postoperative wound infections, and infections in immunocompromised patients.

ExcerptReferenceRelevance
"Cefotetan has not been previously established within orthopedic surgery as a prophylactic intravenous agent."( Use of single agent Cefotetan for Gustilo-Anderson type III open fracture prophylaxis.
Brueggeman, DA; Burdette, SD; Froehle, AW; Murray, VA; Prayson, MJ; Via, GG, 2023
)
1.96
"Cefotetan has limited availability, and substitutions are utilized increasingly."( Impact of surgical site infections on length of stay and costs in selected colorectal procedures.
Mahmoud, NN; Saunders, WB; Turpin, RS; Yang, G, 2009
)
1.07
"Cefotetan disodium has been given by zero order intravenous infusion at 75.8 mg/h to four healthy male volunteers over a 24-h period. "( Pharmacokinetics and tolerance of a 24-h infusion of cefotetan disodium (with and without loading dose) in normal Caucasian volunteers.
Adam, HK; Donnelly, RJ; Houghton, HL; Yates, RA; Young, J, 1983
)
1.96
"Cefotetan has been studied in different surgical specialties in prophylaxis and treatment of postoperative infections for its particularly broad spectrum of activity, covering both aerobic and anaerobic organisms, and for the very low incidence of side-effects."( Prevention and control of surgical infections.
Bertelli, A; Germiniani, R, 1992
)
1
"Cefotetan has been compared with two regimens of combination antibiotic therapy in the treatment of peritonitis and serious intra-abdominal sepsis. "( Cefotetan in the treatment of serious intra-abdominal sepsis: a controlled clinical trial.
Karran, SJ; Scott, SD, 1987
)
3.16
"Cefotetan has shown good clinical efficacy in intra-abdominal, obstetric and gynaecological infections, postoperative wound infections, and infections in immunocompromised patients - all of which are often complicated due to their polymicrobial nature or by the presence of anaerobic pathogens."( Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Richards, DM; Ward, A, 1985
)
2.43

Actions

ExcerptReferenceRelevance
"Cefotetan can cause severe immune hemolytic anemia that may persist long after the drug is discontinued. "( Persistence of cefotetan on red blood cells.
Dake, LR; Davenport, RD; Judd, WJ, 2004
)
2.12

Treatment

Cefotetan-treated patients had significantly fewer postoperative infections overall (P less than 0.05) and there were no wound infections recorded in this group. One patient developed diarrhoea of moderate severity and 2 patients in the same group developed minor increases of liver transaminases.

ExcerptReferenceRelevance
"Cefotetan-treated patients had significantly fewer postoperative infections overall (P less than 0.05) and there were no wound infections recorded in this group."( A comparative trial between cefotetan and cephazolin for wound sepsis prophylaxis during elective upper gastrointestinal surgery with an investigation of cefotetan penetration into the obstructed biliary tree.
Cooper, MJ; Leaper, DJ; Turner, A, 1986
)
1.29
"One cefotetan treated patient developed diarrhoea of moderate severity and 2 patients in the same group developed minor increases of liver transaminases."( Comparative toxicity of gentamicin and cefotetan.
Bergmark, J; Hultberg, B; Linderholm, H; Norrby, R; Trollfors, B, 1986
)
1.02

Toxicity

ExcerptReferenceRelevance
" Except for the small subset of patients receiving concomitant immunosuppressive therapy, CTN appeared to be as safe and effective as CFX when used for surgical prophylaxis."( A comparative evaluation of the safety and efficacy of cefotetan and cefoxitin in surgical prophylaxis.
Danziger, LH; Rodvold, KA; Shwed, JA; Wojtynek, J, 1991
)
0.53
" No toxic ocular side effects could be detected by electroretinography (ERG) or light and electron microscopy up to and including a single intravitreal dose of 1000 micrograms."( Toxicity and clearance of intravitreal cefotetan.
Aichberger, HP; Allerberger, F; Mayer, W; Philipp, W; Pümpel, B; Schmid, K; Steiner, HJ, 1990
)
0.55
" In most cases, the adverse reactions were local, mild and negligible."( Efficacy and safety of cefotetan in the treatment of complicated urinary tract infections: clinical experience in a selective and single study.
Barbuti, S; Germinario, C; Gesualdo, L; Quarto, M; Schena, FP; Viggiani, N, 1989
)
0.59
" From these results, the non toxic effective dose level and the toxic dose level of THR-221 were estimated to be 500 mg/kg/day and more than 2000 mg/kg/day respectively, for male and female dogs."( [Five-week subacute intravenous toxicity study of cefodizime sodium in dogs].
Hirota, T; Irimura, K; Kurokawa, K; Morita, K; Nakano, S; Yada, H, 1988
)
0.27
" These results suggest that a single dose of cefotetan is equally effective and as safe as multiple-dose cefoxitin for prophylaxis in patients undergoing hysterectomy."( Comparative effectiveness and safety of cefotetan and cefoxitin as prophylactic agents in patients undergoing abdominal or vaginal hysterectomy.
Berkeley, AS; Cavanagh, D; Freedman, KS; Ledger, WJ; Orr, JW; Pastorek, JG; Sevin, BU, 1988
)
0.8
" No gastrointestinal or hepatic adverse reactions were observed in the gentamicin treated patients."( Comparative toxicity of gentamicin and cefotetan.
Bergmark, J; Hultberg, B; Linderholm, H; Norrby, R; Trollfors, B, 1986
)
0.54
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

The pharmacokinetic behaviors of the epimers of cefotetan disodium after a single intravenous injection dose in healthy Chinese volunteers were explored in this study. The half-life (3 h) was longer than that of Cefazolin.

ExcerptReferenceRelevance
" The purpose of the study was to compare cefoxitin, cefotetan, ceftizoxime, cefotaxime (CT), desacetylcefotaxime (DACT), and CT/DACT (1:1 ratio) by integrating their microbiologic activity against clinical isolates of Bacteroides fragilis with their pharmacokinetic properties."( Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.
Del Bene, VE; Friedrich, LV; Kays, MB; White, RL,
)
0.38
" Based on these predicted pharmacokinetic parameters, we calculated the plasma concentration profiles of these drugs in humans and found a good agreement between the predicted and observed values."( Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals.
Hanano, M; Iga, T; Kawaguchi, Y; Matsushita, H; Sawada, Y; Sugiyama, Y; Suzuki, H, 1990
)
0.53
"6 ml/min and it was found to be the reason why the serum half-life time was longer than that reported for normal volunteers."( [A pharmacokinetic study of antibiotics in patients with benign prostatic hypertrophy].
Abe, S; Fujita, K; Hara, T; Murayama, T; Sayama, T; Sugimoto, M, 1985
)
0.27
" The half-life of cefotetan (176 min) was significantly longer than that of cefoxitin (49 min)."( Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers.
Carver, PL; Nightingale, CH; Quintiliani, R, 1989
)
0.84
"The pharmacokinetic profile of cefotetan was studied in a group of hospitalized patients."( Pharmacokinetic profile of cefotetan in different clinical conditions.
Cicchetti, F; Fraschini, F; Meroni, M; Mezzetti, M; Scaglione, F; Scarpazza, G; Scarpazza, P, 1988
)
0.86
" The pharmacokinetic parameters for cefotetan were calculated according to a two-compartment open model."( Cefotetan pharmacokinetics in volunteers with various degrees of renal function.
Doret, BA; LeFrock, JL; Onesti, G; Schwartz, A; Smith, BR; Thyrum, PT; Yeh, C; Zimmerman, JJ, 1986
)
1.99
" The pharmacokinetic parameters for cefotetan were calculated on the basis of a two-compartment open model."( Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.
Hirano, S; Ikeda, A; Kuroda, K; Motoi, I; Ohkawa, M; Okasho, A; Sawaki, M; Shimamura, M; Shoda, R; Sugata, T; Tokunaga, S, 1983
)
0.86
"In animal pharmacokinetic studies the biological half-lives of cefotetan were 13."( Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic.
Imamura, K; Matsuzawa, T; Ozaki, H; Sakai, T; Shibata, M; Shiobara, Y; Suzuki, H; Tachibana, A; Yano, K; Yoshida, T, 1983
)
0.77
" The pharmacokinetic findings are in good agreement with theoretical predictions based on single intravenous bolus doses of cefotetan and suggest that a loading dose, followed by an infusion would be suitable regime for cases of severe infection."( Pharmacokinetics and tolerance of a 24-h infusion of cefotetan disodium (with and without loading dose) in normal Caucasian volunteers.
Adam, HK; Donnelly, RJ; Houghton, HL; Yates, RA; Young, J, 1983
)
0.72
"The pharmacokinetic parameters of cefotetan were determined in six healthy adults after intramuscular (im) and intravenous (iv) administration of a single dose."( Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers.
Acar, JF; Guibert, J; Kitzis, MD; Yvelin, C, 1983
)
0.78
"5%), when used as a diluent, had no effect on the pharmacokinetic parameters of cefotetan."( Pharmacokinetics and tolerance of single intramuscular doses of cefotetan in normal Caucasian volunteers.
Adam, H; Cockshott, ID; Donnelly, RJ; Houghton, HL; Wardleworth, A; Yates, RA, 1983
)
0.73
" The half-life (3 h) of cefotetan was longer than that of cefazolin."( Pharmacokinetics of cefotetan (YM09330) in humans.
Kikuchi, Y; Komiya, M; Koyama, M; Nakagawa, K; Tachibana, A; Yano, K, 1982
)
0.89
" A long serum half-life and resistance to beta-lactamase hydrolysis have made cefotetan an attractive chemotherapeutic agent, and the results of clinical trials worldwide have demonstrated its efficacy in a wide variety of clinical situations."( Clinical pharmacokinetics of cefotetan.
Albanese, J; Martin, C; Thomachot, L, 1994
)
0.81
"An in vitro pharmacodynamic system has been successfully adapted to simulate in vivo antimicrobial pharmacokinetics under anaerobic conditions."( Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
Krinke, AJ; Moody, JA; Rotschafer, JC; Vance-Bryan, K; Walker, KJ; Zabinski, RA, 1993
)
0.29
" Pharmacokinetic parameters were determined after a single intravenous bolus dose of 1 g (10 patients) or 2 g (17 patients)."( Pharmacokinetics and clinical study of cefotetan in bile: prophylactic use in biliary tract surgery.
Blot, P; Bosio, AM; Cherrier, P; Fauvelle, F; Gueye, S; Perrin, P; Richer, R; Tinel, P, 1993
)
0.56
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Despite being widely used in the treatment of various infections, little information is available on the pharmacokinetic properties of cefotetan disodium in Chinese subjects."( Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study.
Chen, H; Li, Z; Liu, Y; Lv, Y; Shi, S; Zheng, H, 2010
)
0.82
" No significant differences in pharmacokinetic parameters were noted by sex in the multiple-dose phase."( Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study.
Chen, H; Li, Z; Liu, Y; Lv, Y; Shi, S; Zheng, H, 2010
)
0.62
"The pharmacokinetic behaviors of the epimers of cefotetan disodium (R-CTT, S-CTT) after a single intravenous injection dose in healthy Chinese volunteers were explored in this study."( Pharmacokinetic differences between the epimers of cefotetan disodium after single intravenous injection in healthy Chinese volunteers.
Di, B; Hang, TJ; Huang, LL; Jiang, Y; Liu, MH; Ma, PC; Su, MX, 2011
)
0.88
" The objective of this study was to evaluate the pharmacokinetic profile and tolerability of single and multiple intravenous doses of cefotetan disodium in healthy Chinese volunteers."( Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers.
Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y, 2020
)
0.99
" Pharmacokinetic parameters were calculated and analyzed statistically."( Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers.
Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y, 2020
)
0.79

Bioavailability

ExcerptReferenceRelevance
" The mean +/- SD maximum plasma concentration, time to maximum concentration, terminal half-life, and absolute bioavailability after intramuscular injection were 75."( Absolute bioavailability and noncompartmental analysis of intravenous and intramuscular Cefotan (cefotetan) in normal volunteers.
Cohen, A; Thyrum, P; Zimmerman, J, 1989
)
0.49
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The normal age-related changes in cefotetan kinetics were relatively small and dosage adjustment was not necessary for normal elderly subjects. It is concluded that the pharmacokinetic disposition of cefatetan is similar in Caucasian and Japanese subjects and that the long elimination half-life, lack of deactivation, and lack of side effects are beneficial.

ExcerptRelevanceReference
" Agents with longer half lives allowing twice daily dosing (cefmetazole and cefotetan) were as effective and less expensive than multiple doses of short-acting agents."( Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.
Hopkins, JA; Lami, JL; Wilson, SE, 1991
)
0.51
" As estimates of pharmacodynamic activity, time below the MIC (T less than MIC) and percentage of the dosing interval below the MIC (% INT less than MIC) were calculated for individual isolates using total and unbound serum concentrations."( Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.
Del Bene, VE; Friedrich, LV; Kays, MB; White, RL,
)
0.13
" Clinical intervention strategies include the use of antimicrobial order sheets, standardized dosage regimens, restriction policies for certain antimicrobial agents, and position statements on the use of restricted agents."( Integration of clinical and administrative strategies to reduce expenditures for antimicrobial agents.
Corrao, WM; Fisher, AE; Hess, DA; Johnson, PN; Mahoney, CD, 1990
)
0.28
" Once the recommendation was approved by the medical staff, an intense educational program was instituted, and all orders for cefoxitin were converted to cefotetan with appropriate dosage modifications."( Formulary conversion of cefoxitin usage to cefotetan: experience at a large teaching hospital.
Briceland, LL; Nightingale, CH; Quintiliani, R; Smith, KS, 1989
)
0.74
" The maximum urinary cefotetan concentrations occurred during the first 2 hours after dosing by both routes of administration."( Absolute bioavailability and noncompartmental analysis of intravenous and intramuscular Cefotan (cefotetan) in normal volunteers.
Cohen, A; Thyrum, P; Zimmerman, J, 1989
)
0.81
" Against Bacteroides fragilis, neither cefoxitin nor cefotetan exhibited free serum inhibitory titres greater than 1:8 at the end of their respective dosing intervals."( Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers.
Carver, PL; Nightingale, CH; Quintiliani, R, 1989
)
0.76
" In theory, a prolonged PAE could influence the dosage regimentation of selective antibiotics."( Post-antibiotic effect in Bacteroides fragilis group.
Clausz, JC; Edmiston, CE; Goheen, MP; Siverhus, DJ,
)
0.13
" Twelve-hourly dosing with cefotetan appears to be as effective and well tolerated in regional peritonitis as treatment with shorter-acting agents."( Cephalosporin therapy in intra-abdominal infection: comparative studies of cefotetan, latamoxef and cefoxitin.
Wilson, SE, 1988
)
0.8
" Samples of blood and maxillary sinus mucous membrane were taken in eight patients 2 h after dosing during the third day of therapy to evaluate drug concentration."( Multidisciplinary approach to the therapy of chronic sinusitis.
Bassetti, D; Concia, E; Sampietro, M; Solbiati, M, 1988
)
0.27
" Its elimination half-life of three hours or more allows a twice-daily dosage schedule."( Cefotetan: comparative and noncomparative studies in obstetric and gynecologic infections.
Knuppel, RA; Lake, M; O'Bryan, D, 1988
)
1.72
" Recommendations for the dosing of cefotetan in renal-impaired patients are given."( Cefotetan pharmacokinetics in volunteers with various degrees of renal function.
Doret, BA; LeFrock, JL; Onesti, G; Schwartz, A; Smith, BR; Thyrum, PT; Yeh, C; Zimmerman, JJ, 1986
)
1.99
" The normal age-related changes in cefotetan kinetics were relatively small and dosage adjustment was not necessary for normal elderly subjects requiring cefotetan."( Pharmacokinetics of cefotetan in elderly subjects after intramuscular administration.
Mignini, F; Prenna, M; Ripa, S, 1987
)
0.87
" In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit."( Cefotetan in the treatment of obstetric and gynecologic infections.
Poindexter, AN; Ritter, M; Sweet, R, 1986
)
1.93
" Thus, with its convenient twice daily dosage schedule, cefotetan would appear to be a useful addition to a rapidly expanding group of antibacterial agents."( Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Richards, DM; Ward, A, 1985
)
1.96
" Cefotetan produced high peak and trough plasma and urine concentrations with a twice-daily dosing schedule."( Preliminary report on a comparative trial of cefotetan and cefoxitin in the treatment of urinary tract infections.
Childs, SJ; Cox, CE; Lesky, WC; Mirelmant, S; Wells, WG, 1983
)
1.44
" Daily dosage of CTT ranged from 15 to 123 mg/kg, and 266 patients (93."( [Comprehensive evaluation of cefotetan in pediatrics].
Aoyama, R; Fujii, R; Fujita, K; Izumi, Y; Maruyama, S; Meguro, H; Nagamatsu, I; Okuno, A; Sanae, N; Yoshioka, H, 1983
)
0.56
" Based on the above clinical results, it can be concluded that, in the treatment of complicated urinary tract infections, we can expect CTT to provide the same therapeutic efficacy as CMZ when its dosage is the same or even half thereof."( [Double-blind comparison of cefotetan and cefmetazole in complex urinary tract infections].
Arakawa, S; Fujimura, N; Ishigami, J; Ishino, T; Ishito, N; Kamidono, S; Kurokawa, K; Nihira, H; Ohmori, H; Umezu, K, 1983
)
0.56
" It is concluded that the pharmacokinetic disposition of cefotetan is similar in Caucasian and Japanese subjects and that the long elimination half-life, lack of detectable metabolism and high urinary excretion will result in plasma and urine concentrations in excess of the MIC of sensitive bacteria on a twice daily dosing regime."( Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male Caucasian volunteers.
Adam, HK; Charlesworth, EA; Donnelly, RJ; Houghton, HL; Laws, EA; Yates, RA, 1983
)
0.75
" No adverse reactions were observed in the above cases and 2 other patients, during and after the dosage of 30-60 mg/kg/day for 4-11 days."( [Clinical evaluation of cefotetan in pediatrics].
Fujita, K; Maruyama, S; Sakata, H; Sanae, N; Yoshioka, H, 1983
)
0.57
" When the dosage rate was 10 mg/kg, the mean serum levels were as follows; 58."( [Experimental and clinical evaluation of cefotetan in pediatrics].
Akita, H; Iwasaki, Y; Iwata, S; Jozaki, K; Kanemitsu, T; Kojima, Y; Osano, M; Sunakawa, K; Tojo, M; Wakabayashi, R, 1983
)
0.53
" When CTT was administered in a dosage of 10 mg/kg by intravenous drip infusion, the drug could still be detected in the serum as long as 12 hours later in some cases."( [Experimental and clinical evaluation of a new cephamycin antibiotic, cefotetan, in pediatrics].
Chikaoka, H; Hirama, Y; Nakazawa, S; Narita, A; Niino, K; Oka, S; Sato, H; Suzuki, H, 1983
)
0.5
" Absorption and excretion CTT was administered to children at a dosage of 10 mg/kg and 20 mg/kg as a one-shot intravenous injection or as a 1-hour intravenous drip infusion."( [Experimental and clinical evaluation of cefotetan in pediatrics].
Hori, M; Horiuchi, K; Kita, A; Kouda, N; Kumagai, K; Kurosu, Y; Sugita, M; Takahashi, T; Toyonaga, Y; Yoshino, N, 1983
)
0.53
"53 microgram/ml for sisomicin at 90 minutes after dosing administration."( [Pharmacokinetics of cefotetan and an aminoglycoside preparation in combined administration. 1. Individual quantification of cefotetan and sisomicin by bioassay and their absorption, distribution, and excretion in rats when given together].
Ikeda, C; Tachibana, A; Yano, K, 1982
)
0.58
" The recommended dosage is 1g every 12 hours, increasing to 2g in severe infections and 3g in life-threatening infections."( Clinical pharmacokinetics of cefotetan.
Albanese, J; Martin, C; Thomachot, L, 1994
)
0.58
" Patients were discharged when they had received their assigned dosage of cefotetan, were afebrile (temperature < 100."( Randomized trial of single-dose versus multiple-dose cefotetan for the postpartum treatment of intrapartum chorioamnionitis.
Chapman, SJ; Owen, J, 1997
)
0.78
" Pharmacokinetic data suggest benefit from higher cefotetan and cefoxitin dosing in obese patients."( Higher versus Lower Dose of Cefotetan or Cefoxitin for Surgical Prophylaxis in Patients Weighing One Hundred Twenty Kilograms or More.
Avdic, E; Banoub, M; Cosgrove, SE; Curless, MS; Jarrell, AS; Rock, C; Smith, JM, 2018
)
1.03
" Interventions were any antibiotic prophylaxis (any dosage regimen, any route of administration or at any time during delivery or the puerperium)."( Antibiotic prophylaxis for operative vaginal delivery.
Choobun, T; Islam, QM; Liabsuetrakul, T; Peeyananjarassri, K, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency12.43120.044717.8581100.0000AID485294; AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency25.11890.631035.7641100.0000AID504339
AR proteinHomo sapiens (human)Potency0.00070.000221.22318,912.5098AID743042
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency15.84890.035520.977089.1251AID504332
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency28.18383.548119.542744.6684AID743266
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency7.07950.01789.637444.6684AID588834
DNA polymerase eta isoform 1Homo sapiens (human)Potency30.13130.100028.9256213.3130AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency11.22020.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency7.94330.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency4.88110.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency44.66840.031622.3146100.0000AID588579
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)69.30000.270026.3638100.0000AID504723
DNA dC->dU-editing enzyme APOBEC-3A isoform aHomo sapiens (human)IC50 (µMol)29.60001.480014.526761.2000AID504724
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)79.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (58)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (241)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID574530Antimicrobial activity against Prevotella bivia assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1211878Unbound biliary clearance in iv dosed rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID574967Antimicrobial activity against Actinomyces odontolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID574760Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1399265Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID157251Antibacterial activity against anaerobic Peptococcus prevoti 12811993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID574979Antimicrobial activity against Actinomyces meyeri assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574740Antimicrobial activity against Peptostreptococcus anaerobius after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574518Antimicrobial activity against Prevotella intermedia after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574524Antimicrobial activity against Prevotella oralis after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID164095Antibacterial activity against aerobic Pseudomonas aeruginosa X239 strain1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID1399269Antimicrobial activity against Klebsiella pneumoniae isolate SJ 2 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID574490Antimicrobial activity against Bacteroides vulgatus after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1399271Antimicrobial activity against Klebsiella pneumoniae isolate SJ 4 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1399272Antimicrobial activity against Klebsiella pneumoniae isolate SJ 5 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID574985Antimicrobial activity against Actinomyces naeslundii assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID394494Antimicrobial activity against Escherichia coli MC4100 harboring pACYC184 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534391Antibacterial activity against Escherichia coli JM109 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1211870Total biliary clearance in iv dosed rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID574752Antimicrobial activity against Anaerococcus prevotii after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574492Antimicrobial activity against Bacteroides ovatus after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID534382Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID574726Antimicrobial activity against Prevotella oralis assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574782Antimicrobial activity against Actinomyces odontolyticus after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID83803Antibacterial activity against aerobic Haemophilus influenzae RES 761993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574969Antimicrobial activity against Actinomyces israelii after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574991Antimicrobial activity against Bifidobacterium adolescentis assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574756Antimicrobial activity against Anaerococcus prevotii assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574502Antimicrobial activity against Bacteroides caccae assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID543419Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID574732Antimicrobial activity against Fusobacterium varium after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1399268Antimicrobial activity against Klebsiella pneumoniae isolate SJ 1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID574750Antimicrobial activity against Peptostreptococcus micros assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574977Antimicrobial activity against Actinomyces meyeri assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID574758Antimicrobial activity against Peptoniphilus asaccharolyticus after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID535691Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID574995Antimicrobial activity against Bifidobacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574724Antimicrobial activity against Prevotella buccae assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574987Antimicrobial activity against Bifidobacterium adolescentis after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID207724Antibacterial activity against aerobic Staphylococcus aureus X1.1 strain1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574516Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574488Antimicrobial activity against Bacteroides distasonis after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574520Antimicrobial activity against Prevotella bivia after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574522Antimicrobial activity against Prevotella buccae after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574534Antimicrobial activity against Prevotella buccae assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574510Antimicrobial activity against Bacteroides vulgatus assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1211828Drug excretion in iv dosed human assessed as compound excreted into bile after 7 hrs by duodenal perfusion method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1399276Antimicrobial activity against Escherichia coli isolate SJ 4 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID71150Antibacterial activity against anaerobic Eubacterium aerofaciens 12351993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574526Antimicrobial activity against Prevotella intermedia assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID574997Antimicrobial activity against Bifidobacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574975Antimicrobial activity against Actinomyces meyeri after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574776Antimicrobial activity against Clostridium difficile after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID157382Antibacterial activity against anaerobic Peptostreptococcus anaerobius 14511993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID41560Antibacterial activity against anaerobic Bacteroides vulgatus 12111993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574484Antimicrobial activity against Bacteroides thetaiotaomicron after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID543423Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1211884Total biliary clearance in iv dosed dog2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID543415Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID574746Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID41404Antibacterial activity against anaerobic Bacteroides fragilis 1111993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID574770Antimicrobial activity against Clostridium perfringens after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID575005Antimicrobial activity against Eubacterium sp. after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574774Antimicrobial activity against Clostridium perfringens assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID72252Antibacterial activity against anaerobic Fusobacterium necrophorum 6054A1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574742Antimicrobial activity against Peptostreptococcus micros after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID535694Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID574506Antimicrobial activity against Bacteroides distasonis assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1399274Antimicrobial activity against Escherichia coli isolate SJ 2 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1399278Antimicrobial activity against Escherichia coli isolate SJ 6 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID574981Antimicrobial activity against Actinomyces naeslundii after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574494Antimicrobial activity against Bacteroides fragilis assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID574754Antimicrobial activity against Anaerococcus prevotii assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574504Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574528Antimicrobial activity against Prevotella intermedia assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574734Antimicrobial activity against Fusobacterium necrogenes after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574486Antimicrobial activity against Bacteroides caccae after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574973Antimicrobial activity against Actinomyces israelii assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1399280Antimicrobial activity against Escherichia coli ATCC 25922 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID574993Antimicrobial activity against Bifidobacterium sp. after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1399263Antimicrobial activity against tolC deficient Escherichia coli JW5503-1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID41416Antibacterial activity against anaerobic Bacteroides melaninogenicus 1856/281993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574772Antimicrobial activity against Clostridium perfringens assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1211808Drug excretion in iv dosed dog assessed as compound excreted into bile2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID574999Antimicrobial activity against Eubacterium lentum after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574780Antimicrobial activity against Clostridium difficile assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574512Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574971Antimicrobial activity against Actinomyces israelii assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID587727Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-18-pLBII after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID574764Antimicrobial activity against Finegoldia magna after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID534385Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1399273Antimicrobial activity against Escherichia coli isolate SJ 1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID574482Antimicrobial activity against Bacteroides fragilis after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574965Antimicrobial activity against Actinomyces odontolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID394492Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc4 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID575009Antimicrobial activity against Eubacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574744Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574738Antimicrobial activity against Fusobacterium mortiferum after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1211867Unbound biliary clearance in iv dosed human after 7 hrs by duodenal perfusion method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1399277Antimicrobial activity against Escherichia coli isolate SJ 5 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID394495Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc4 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1399266Antimicrobial activity against Proteus mirabilis ATCC 25933 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID543427Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574498Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID67876Antibacterial activity against aerobic Enterobacter aerogenes C321993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID575001Antimicrobial activity against Eubacterium lentum assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574496Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574778Antimicrobial activity against Clostridium difficile assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID574532Antimicrobial activity against Prevotella bivia assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID70642Antibacterial activity against aerobic Escherichia coli EC141993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID1399279Antimicrobial activity against Escherichia coli ATCC 35218 expressing TEM-1 beta lactamases after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID534379Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1399275Antimicrobial activity against Escherichia coli isolate SJ 3 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1399270Antimicrobial activity against Klebsiella pneumoniae isolate SJ 3 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID41435Antibacterial activity against anaerobic Bacteroides thetaiotaomicron 14381993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID394493Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc1 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID41406Antibacterial activity against anaerobic Bacteroides fragilis 18771993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID587728Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-1-pLBII after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID160390Antibacterial activity against anaerobic Propionibacterium acnes 791993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID157385Antibacterial activity against anaerobic Peptostreptococcus intermedius 12641993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID1211848Total biliary clearance in iv dosed human after 7 hrs by duodenal perfusion method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID574762Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1211802Drug excretion in iv dosed rat assessed as compound excreted into bile2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID534388Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID574514Antimicrobial activity against Bacteroides ovatus assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID394496Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc1 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574508Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID575007Antimicrobial activity against Eubacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID41407Antibacterial activity against anaerobic Bacteroides fragilis 1936B1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID575003Antimicrobial activity against Eubacterium lentum assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID574766Antimicrobial activity against Finegoldia magna assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID51019Antibacterial activity against anaerobic Clostridium perfringens 811993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID206198Antibacterial activity against aerobic Staphylococcus epidermidis 2221993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574983Antimicrobial activity against Actinomyces naeslundii assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574768Antimicrobial activity against Finegoldia magna assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574728Antimicrobial activity against Prevotella oralis assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID41417Antibacterial activity against anaerobic Bacteroides melaninogenicus 27361993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID1399260Antimicrobial activity against Acinetobacter baumannii ATCC 19606 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID51136Antibacterial activity against anaerobic Clostridium septicum 11281993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574748Antimicrobial activity against Peptostreptococcus micros assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID50854Antibacterial activity against anaerobic Clostridium difficile 2994 strain1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID1399264Antimicrobial activity against Klebsiella pneumoniae ATCC 33495 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID574989Antimicrobial activity against Bifidobacterium adolescentis assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID587729Antimicrobial activity against Escherichia coli DH5alpha carrying empty pBC-SK after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID535697Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID543411Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1399262Antimicrobial activity against Escherichia coli BW25113 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID157246Antibacterial activity against anaerobic Peptococcus asaccharolyticus 13021993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID1211886Unbound biliary clearance in iv dosed dog2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID94371Antibacterial activity against aerobic Klebsiella pneumoniae X261993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574736Antimicrobial activity against Fusobacterium nucleatum after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID394497Antimicrobial activity against Escherichia coli MC4100 harboring pBCSK plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID72264Antibacterial activity against anaerobic Fusobacterium symbiosum 14701993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID574500Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574730Antimicrobial activity against Porphyromonas asaccharolytica after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID41111Antibacterial activity against anaerobic Bacteroides corrodens 18741993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID208924Antibacterial activity against aerobic Streptococcus pneumoniae PARK1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
Synthesis and anaerobic activity of novel 1-carba-1-dethiacephalosporins.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (483)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990302 (62.53)18.7374
1990's98 (20.29)18.2507
2000's45 (9.32)29.6817
2010's32 (6.63)24.3611
2020's6 (1.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.49 (24.57)
Research Supply Index6.49 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index101.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials137 (26.25%)5.53%
Reviews19 (3.64%)6.00%
Case Studies49 (9.39%)4.05%
Observational0 (0.00%)0.25%
Other317 (60.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 2 Study of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery [NCT01220661]Phase 2312 participants (Actual)Interventional2010-10-31Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Prospective Randomized Control Study of Clinical Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate [NCT04726046]Phase 1529 participants (Actual)Interventional2014-04-01Completed
A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Ertapenem Sodium (MK0826) Versus Cefotetan for the Prophylaxis of Surgical Site Infection Following Elective Col [NCT00090272]Phase 3952 participants (Actual)Interventional2002-04-30Completed
A Randomized Controlled Trial of the Effect of Prophylactic Antibiotics on the Infection Rate in Postpartum Third and Fourth Degree Perineal Tear Repairs [NCT00186082]147 participants (Actual)Interventional2003-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]